BMY Mar 2025 46.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:17AM EDT. Market open.
| Previous close | 1.1800 |
| Open | 1.1700 |
| Bid | 1.0800 |
| Ask | 1.4700 |
| Strike | 46.00 |
| Expiry date | 2025-03-21 |
| Day's range | 1.1700 - 1.1700 |
| Contract range | N/A |
| Volume | |
| Open interest | 260 |
Business WireU.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J., October 03, 2024--U.S. FDA Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo...
Investor's Business DailyBristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
ZacksSTTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
© 2024 Yahoo. All rights reserved.